Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioIndustry Association
Biotech
British biotech funding‘s ‘signs of recovery,’ but still no IPOs
The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign of recovery.”
James Waldron
Apr 27, 2026 6:59am
AstraZeneca to help build life science research cluster in China
Mar 28, 2019 10:31am
As the U.K. preps to leave the EU, what will happen to research?
Nov 2, 2018 10:46am
BIA backs tax changes to 'democratize' biotech investing
May 16, 2018 9:43am
Shock U.K. election result creates uncertainty for biotech
Jun 12, 2017 3:28am
Brexit: Why U.K. life science remains optimistic
Mar 29, 2017 6:00am
